, 2010). Given the complex nature of antibody elicitation, whether these factors

influence the rate of antibody formation is unknown. With alternative enzyme replacement therapies for type 1 Gaucher disease available, physicians considering treatment options will require high-quality data on the development of antibodies in patients treated with imiglucerase or velaglucerase alfa. We therefore developed and validated a panel of highly sensitive and equivalent assays for the detection and characterization of anti-velaglucerase alfa and anti-imiglucerase antibodies. Identical methods were developed to evaluate patient sera for anti-velaglucerase alfa and anti-imiglucerase click here antibodies. The bridge electrochemiluminescent (ECL) immunoassay, in which the drug is alternatively labeled with capture or detection functional groups, detected all immunoglobulin subclasses and was considered the antibody screening assay. The radioimmunoprecipitation

(RIP) assay was confirmatory Staurosporine datasheet for the presence of IgG antibodies, and the Ig subclass electrochemiluminescent immunoassays were confirmatory assays for the presence of IgA, IgM, and IgE antibodies. A diagram of the testing flowchart is shown in Fig. 1. The antibody screening assays and IgG assays were calibrated and quantitative, using human antibody-positive controls. The IgA, IgM, and IgE assays were semi-quantitative and utilized synthetic positive controls, since naturally occurring IgA, IgM, or IgE antibodies against velaglucerase alfa or imiglucerase were not available. To further test whether antibodies neutralized enzyme activity in vitro, assays were also developed to measure inhibition in vitro of velaglucerase alfa and imiglucerase hydrolysis of the substrate 4-nitrophenyl-β-d-glucopyranoside. The ECL assays were read on a SECTOR™ Imager 2400 (Meso Scale Discovery, Gaithersburg, MD) using Meso

Scale Discovery Workbench® Software. Streptavidin-coated high bind MA2400 96-microwell plates were also purchased from Meso Scale Discovery, as were the Sulfo-TAG™ NHS-Ester Kit for ruthenium-complex labeling and the read buffer S (4×) for ECL assay. Flat-bottomed Nunc MaxiSorp ELISA plates were purchased from Nalge Nunc International selleck kinase inhibitor (Rochester, NY). EZ-Link® Sulfo-NHS-LC-Biotinylation Kits and BCA™ Protein Assay Kits were acquired from Pierce (Pierce Protein Research Products from Thermo Fisher Scientific, Rockford, IL). Protein G Sepharose 4 Fast Flow columns and ECL Blocker B were acquired from GE Healthcare (Piscataway, NJ). Dulbecco’s Phosphate Buffered Saline solution (DPBS) was obtained from Invitrogen (Carlsbad, CA). Protease-free bovine serum albumin (BSA) was obtained from American Bioanalytical (Natick, MA). Purified sheep anti-glucocerebrosidase polyclonal antibody and mouse anti-glucocerebrosidase monoclonal antibody were both prepared by Shire Human Genetic Therapies.